These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19209029)

  • 1. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
    Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
    Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
    Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
    Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
    Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
    Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
    Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
    Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
    Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
    Tanaka R; Takii Y; Shibata Y; Ariyama H; Qin B; Baba E; Kusaba H; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):279-85. PubMed ID: 15875187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
    Lee JL; Ahn JH; Choi MK; Kim Y; Hong SW; Lee KH; Jeong IG; Song C; Hong BS; Hong JH; Ahn H
    Br J Cancer; 2014 May; 110(10):2472-8. PubMed ID: 24736579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
    Zhao CH; Yuan SJ; Wang Y; Ge FJ; Luo WD; Xu JM
    Ai Zheng; 2007 Dec; 26(12):1299-303. PubMed ID: 18076790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
    Adema AD; Laan AC; Myhren F; Fichtner I; Verheul HM; Sandvold ML; Peters GJ
    Int J Oncol; 2010 Jan; 36(1):285-94. PubMed ID: 19956857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
    Zoli W; Ricotti L; Tesei A; Ulivi P; Gasperi Campani A; Fabbri F; Gunelli R; Frassineti GL; Amadori D
    Clin Cancer Res; 2004 Feb; 10(4):1500-7. PubMed ID: 14977854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
    Verderame F; Russo A; Di Leo R; Badalamenti G; Santangelo D; Cicero G; Valerio MR; Gulotta G; Tomasello G; Gebbia N; Fulfaro F
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii68-72. PubMed ID: 16760298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.
    Gravett AM; Liu WM; Krishna S; Chan WC; Haynes RK; Wilson NL; Dalgleish AG
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):569-77. PubMed ID: 20490800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice.
    Moschidis A; Papageorgiou A; Atmatzidis K; Tsalis K; Moschidis E; Livanis J; Chrysogelou E; Mourelatos D; Tsavdaridis D; Harlaftis N
    Chemotherapy; 2007; 53(3):153-9. PubMed ID: 17347561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
    Wagner AD; Buechner-Steudel P; Moehler M; Schmalenberg H; Behrens R; Fahlke J; Wein A; Behl S; Kuss O; Kleber G; Fleig WE
    Br J Cancer; 2009 Dec; 101(11):1846-52. PubMed ID: 19904267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
    Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
    Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
    Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.